Merck Acquires HPLC Column Company
SeQuant AB was founded in 1987 and sells nine ZIC-HILIC product lines. HILIC is used to separate polar substances, including many biologically active compounds such as peptides. SeQuant CEO Einar Pontén was named managing director of Merck SeQuant.
Darmstadt, Germany 2/29/08—Merck KGaA has acquired SeQuant AB, a developer of silican-gel and polmer-based sorbents for ZIC-HILIC (zwitterionic hydrophilic interaction chromatography). SeQuant has joined Merck’s Performance & Life Science Chemicals division. “[SeQuant] offers Merck superb opportunities for the future expansion of the chromatography business,” stated Klaus Bischoff, head of Merck Performance & Life Science Chemicals. “By acquiring SeQuant, we are gaining acess to a unique technology in the rapidly growing HILIC application segment for analytical and preparative purposes.” SeQuant’s headquarters in Umeå, Sweden, and all employees will be retained by Merck.
